Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03626103 · ClinicalTrials.gov registry record · NA
Intervention to Prevent Peer Violence & Depressive Symptoms Among At-Risk Adolescents
A NA study of Depressive Disorder and Violence, sponsored by Rhode Island Hospital.
- Active
- Registry status
- NA
- Development phase
- 800
- Enrollment target
- 2
- Study locations
NCT03626103: Active NA study of Depressive Disorder and Violence, sponsored by Rhode Island Hospital.
NCT03626103 is a NA study of Depressive Disorder and Violence that is active but no longer recruiting, run by Rhode Island Hospital. The registered enrollment target is 800 participants, above the 315-participant average among 47 other Depressive Disorder trials with a reported enrollment target (154% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03626103, a NA study of Depressive Disorder and Violence, is active but no longer recruiting, sponsored by Rhode Island Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 800 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this investigation is to test the efficacy of "iDOVE2" (a brief emergency department introductory session and longitudinal automated text-message depression prevention program for high-risk teens), and to determine the most potent and parsimonious combination of intervention components for preventing peer violence and depressive symptoms among at-risk youth.
Primary Outcome
Change from enrollment physical peer violence (score is summed, range 0 - 56)
Conditions Studied
Interventions
- BEHAVIORAL + Brief ED Intervention (BI)
- BEHAVIORAL + Text
Study Locations (2)
Connecticut
- Yale New Haven Hospital - New Haven
Rhode Island
- Rhode Island Hospital/Hasbro Children's Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2025-02 |
| Phase | NA |
What the registry record for NCT03626103 still lists
NCT03626103 is an interventional study that assigns participants to a tested intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, above the 315-participant average among 47 other Depressive Disorder trials with a reported enrollment target (154% higher).
The record links to 2 conditions, with Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which + Brief ED Intervention (BI) is the first listed.
NCT03626103 reports a single indexed study location in Connecticut, Rhode Island.
Frequently Asked Questions
What is clinical trial NCT03626103 about?
NCT03626103 is a clinical study titled "Intervention to Prevent Peer Violence & Depressive Symptoms Among At-Risk Adolescents". The purpose of this investigation is to test the efficacy of "iDOVE2" (a brief emergency department introductory session and longitudinal automated text-message depression prevention program for high-risk teens), and to determine the most potent and parsimonious combination of intervention component...
What is the current status of trial NCT03626103?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 800 participants. The study started on 2018-08-01. Estimated completion is 2025-02.
What conditions does trial NCT03626103 study?
This clinical trial studies the following conditions: Depressive Disorder, Violence.
What interventions are being tested in trial NCT03626103?
The interventions under investigation include: + Brief ED Intervention (BI) (BEHAVIORAL), + Text (BEHAVIORAL).
Who is sponsoring clinical trial NCT03626103?
This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03626103 being conducted?
This trial has 2 study locations across Connecticut, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03626103's enrollment target sits among peer trials
800 5th of 47 higher than 43 of 47 other Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Mental Health Services Engagement Program for Racial and Ethnic Minority Young Adults
RECRUITING · NA
-
Development of a Transdiagnostic Intervention for Adolescents at Risk for Serious Mental Illness
RECRUITING · NA
-
Measurement-Based Care (MBC) Implementation, Effectiveness, and Mechanisms of Change
RECRUITING · NA
-
Research Evaluating Vagal Excitation AND Anatomical Links
RECRUITING · NA
-
Unified Protocol: Community Connections
RECRUITING · NA
-
Enhancing Brain And Mental Health Through Breathing Practice
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI